Meropenem/Vaborbactam in Pediatrics: 2 Cases of CRE Intraabdominal Infection.

Q2 Medicine

Journal of Pediatric Pharmacology and Therapeutics Pub Date : 2025-04-01 Epub Date: 2025-04-14 DOI:10.5863/1551-6776-30.2.263

Ugene Sano, Rachel Meyers, Uzma Hasan, Steven Smoke

{"title":"Meropenem/Vaborbactam in Pediatrics: 2 Cases of CRE Intraabdominal Infection.","authors":"Ugene Sano, Rachel Meyers, Uzma Hasan, Steven Smoke","doi":"10.5863/1551-6776-30.2.263","DOIUrl":null,"url":null,"abstract":"<p><p>Meropenem/vaborbactam is a combination antibiotic with a carbapenem and a carbapenemase inhibitor typically reserved for extensively drug-resistant bacterial infections, such as carbapenem-resistant Enterobacterales (CRE). Meropenem/vaborbactam is approved by the United States Food and Drug Administration for use in adults for complicated urinary tract infections, whereas data in the pediatric population are limited. This case series described the use of meropenem/vaborbactam in 2 pediatric patients, ages 11 and 15, with intraabdominal abscesses from CRE. Both patients had clinically improved after the initiation of meropenem/vaborbactam and reported no complications during their follow-up appointments after the completion of their antibiotic courses. These cases demonstrate the safe and effective use of meropenem/vaborbactam in these 2 pediatric patients. Although meropenem/vaborbactam successfully treated both patients' infections, additional data are needed in this population to determine the safety profile and optimal use for pediatric patients.</p>","PeriodicalId":37484,"journal":{"name":"Journal of Pediatric Pharmacology and Therapeutics","volume":"30 2","pages":"263-267"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12288576/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pediatric Pharmacology and Therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5863/1551-6776-30.2.263","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/14 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Meropenem/vaborbactam is a combination antibiotic with a carbapenem and a carbapenemase inhibitor typically reserved for extensively drug-resistant bacterial infections, such as carbapenem-resistant Enterobacterales (CRE). Meropenem/vaborbactam is approved by the United States Food and Drug Administration for use in adults for complicated urinary tract infections, whereas data in the pediatric population are limited. This case series described the use of meropenem/vaborbactam in 2 pediatric patients, ages 11 and 15, with intraabdominal abscesses from CRE. Both patients had clinically improved after the initiation of meropenem/vaborbactam and reported no complications during their follow-up appointments after the completion of their antibiotic courses. These cases demonstrate the safe and effective use of meropenem/vaborbactam in these 2 pediatric patients. Although meropenem/vaborbactam successfully treated both patients' infections, additional data are needed in this population to determine the safety profile and optimal use for pediatric patients.

查看原文本刊更多论文

美罗培南/瓦波巴坦在儿科的应用：CRE腹腔内感染2例。

美罗培南/瓦波巴坦是一种含有碳青霉烯烯和碳青霉烯酶抑制剂的联合抗生素，通常用于广泛耐药细菌感染，如碳青霉烯耐药肠杆菌（CRE）。美罗培南/瓦波巴坦已被美国食品和药物管理局批准用于成人复杂尿路感染，而儿童人群的数据有限。本病例系列描述了2例11岁和15岁的CRE腹腔内脓肿患儿使用美罗培南/瓦波巴坦。两名患者在开始使用美罗培南/瓦博巴坦后均有临床改善，并且在完成抗生素疗程后的随访中没有出现并发症。这些病例表明，在这2例儿科患者中使用美罗培南/瓦博巴坦是安全有效的。尽管美罗培南/瓦博巴坦成功地治疗了这两名患者的感染，但需要在这一人群中获得额外的数据来确定安全性和儿科患者的最佳使用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Pediatric Pharmacology and Therapeutics Medicine-Pediatrics, Perinatology and Child Health

CiteScore

2.40

自引率

0.00%

发文量

期刊介绍： The Journal of Pediatric Pharmacology and Therapeutics is the official journal of the Pediatric Pharmacy Advocacy Group. JPPT is a peer-reviewed multi disciplinary journal that is devoted to promoting the safe and effective use of medications in infants and children. To this end, the journal publishes practical information for all practitioners who provide care to pediatric patients. Each issue includes review articles, original clinical investigations, case reports, editorials, and other information relevant to pediatric medication therapy. The Journal focuses all work on issues related to the practice of pediatric pharmacology and therapeutics. The scope of content includes pharmacotherapy, extemporaneous compounding, dosing, methods of medication administration, medication error prevention, and legislative issues. The Journal will contain original research, review articles, short subjects, case reports, clinical investigations, editorials, and news from such organizations as the Pediatric Pharmacy Advocacy Group, the FDA, the American Academy of Pediatrics, the American Society of Health-System Pharmacists, and so on.